Framing: negotiate the exit process as carefully as the entry price. Manufacturer programme terms reviewed here reserve rights to modify or cancel offers, while FDA’s evolving GLP-1 communications show why a historical access assumption should not underpin an unconditional long-term commitment. (lilly.com)
Put to: Jesse Dresser and Adam Fein.
Buyer owner: Counsel and CFO.
A good answer should cover these proposed negotiation topics:
- Product-, facility- or state-specific suspension and termination triggers.
- Treatment of minimum commitments when the agreed route cannot be supplied.
- Price-change notice, promotion expiry and withdrawal of programme eligibility.
- Deposits, unused balances, undelivered orders, refunds and replacement costs.
- Recall, complaint and adverse-event cooperation.
- Access to operational records and reasonable transition assistance.
- Responsibility for subcontractors and changes to the dispensing facility.
- Remedies for persistent failures beyond service credits, where negotiable.
Follow-up that tests the answer: “If the proposed route becomes unavailable tomorrow, what money remains at risk, what can we stop paying, and what practical assistance must the counterparty provide?”
Evidence to request: A redlined issue register and exit-cost schedule. Model committed cash, remaining fees and transition effort separately; do not treat an indemnity as proof that losses will be recoverable.
Expert quote — reserved: ________________________________________
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/zepbound